SCHEMBL13837342

SCHEMBL13837342

N#Cc1ccc(-c2cccc(OCCC3CCN(C(=O)OCc4cncs4)CC3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 3/20 0.43
HRH1 P35367 3/20 0.43
HRH3 Q9Y5N1 1/20 0.41
FNTA P49354 5/20 0.40
FNTB P49356 5/20 0.40
PGGT1B P53609 5/20 0.40
CHRM4 P08173 2/20 0.39
MGLL Q99685 1/20 0.39
TEAD1 P28347 1/20 0.38
TEAD3 Q99594 1/20 0.38
FAAH O00519 1/20 0.37
GRIN2B Q13224 1/20 0.37
ENPP2 Q13822 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229515 0.93 HRH2 (0.47) HRH2HRH1HRH3FNTAFNTB
SCHEMBL2227968 0.91 MGLL (0.47) HRH2HRH1FNTAFNTBPGGT1B
SCHEMBL2228392 0.91 TEAD1 (0.45) HRH3CHRM4TEAD1TEAD3FAAH
SCHEMBL2229765 0.87 CHRM4 (0.39) HRH2HRH1HRH3CHRM4MGLL
SCHEMBL2227630 0.86 TEAD1 (0.47) CHRM4TEAD1TEAD3FAAHGRIN2B
SCHEMBL13837118 0.85 HRH2 (0.46) HRH2HRH1HRH3FNTAFNTB
SCHEMBL2227846 0.85 HRH2 (0.44) HRH2HRH1HRH3FNTAFNTB
SCHEMBL2226276 0.85 TEAD1 (0.53) CHRM4TEAD1TEAD3FAAHGRIN2B
SCHEMBL2228518 0.84 CHRM4 (0.39) FNTAFNTBPGGT1BCHRM4FAAH
SCHEMBL2229682 0.82 TEAD1 (0.45) CHRM4MGLLTEAD1TEAD3FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 HRH2 345/4885HRH1 361/4885HRH3 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.